Még nem toboroz
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
Phase 1b/2 Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIde)
2025-523010-89-00· 1/2. fázis· 35Pharma Inc.· Forrás
Még nem toboroz
Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma
2026-526352-31-00· 2. fázis· Fundacion PETHEMA· Forrás
Toboroz
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
2025-524335-39-00· 3. fázis· Gilead Sciences Inc.· Forrás
Toboroz
BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])
NCT07666490· 4. fázis· Chiesi Farmaceutici S.p.A.· Forrás
Toboroz
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· 3. fázis· Hoffmann-La Roche· Forrás
Még nem toboroz
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
NCT07612657· 3. fázis· VIVUS LLC· Forrás
Toboroz
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
NCT07318597· 2. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759· 2. fázis· Eli Lilly and Company· Forrás
Contact: ANGELES Perez Aisa (principal investigator)
Toboroz
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT07545772· 2. fázis· Eli Lilly and Company· Forrás
Contact: ANGELES Perez Aisa (principal investigator)
Toboroz
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546· 2. fázis· ViiV Healthcare· Forrás
Toboroz
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
NCT06980480· 3. fázis· Takeda· Forrás
Toboroz
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
NCT07213778· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
NCT07168434· 3. fázis· Biocodex· Forrás
Toboroz
Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma
NCT07285590· 2. fázis· Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea· Forrás
Contact: María Casanova Espinosa
Toboroz
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
2024-513613-12-00· 1/2. fázis· Novartis Pharma AG· Forrás
Toboroz
Thyroidectomy for Graves' Disease or Amiodarone-induced Thyrotoxicosis
NCT06963203· Andrea Goldmann· Forrás
Contact: Cristina Martines Santos, MD
Toboroz
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095· 3. fázis· GlaxoSmithKline· Forrás
Toboroz
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· 3. fázis· University Of Cologne· Forrás
Toboroz
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· 3. fázis· BeOne Medicines· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478· 2. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin’s Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy
NCT04378647· 2. fázis· Fundacion Geltamo· Forrás
Toboroz
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801· 3. fázis· Gossamer Bio USA, Inc.· Forrás
Toboroz
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06544785· 2. fázis· PETHEMA Foundation· Forrás
Contact: Pau Abrisqueta
Toboroz
A multicenter, phase 2 randomized, open label study to evaluate the efficacy and security of zanubrutinib in combination with obinutuzumab in previously untreated patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (GELLC-10-ZANUBIO)
2023-504647-14-00· 2. fázis· Pethema Fundacion· Forrás
Fut, nem toboroz
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
NCT06456346· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism
2024-511959-18-01· 3. fázis· Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal· Forrás
Fut, nem toboroz
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma
2023-505436-35-00· 3. fázis· Lysarc· Forrás
Toboroz
A multicentric, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of COLIRIOBCN070660 administered topically in patients with moderately severe to severe non-proliferative diabetic retinopathy
2023-505791-30-01· 2/3. fázis· Bcn Peptides S.A.· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311· 3. fázis· ViiV Healthcare· Forrás
Fut, nem toboroz
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
NCT05983250· 3. fázis· Tenax Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide in combination with bortezomib and dexamethasone in people who have Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment.
2023-509859-13-00· 3. fázis· Celgene Corp.· Forrás
Fut, nem toboroz
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT
2024-517008-12-00· 3. fázis· Fundacion PETHEMA· Forrás
Toboroz
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743· 3. fázis· Loxo Oncology, Inc.· Forrás
Toboroz
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
NCT05303532· 3. fázis· Astrazeneca AB· Forrás
Fut, nem toboroz
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156· 3. fázis· Geron Corporation· Forrás
Fut, nem toboroz
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318· 3. fázis· German CLL Study Group· Forrás
Fut, nem toboroz
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945· 3. fázis· Actelion· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493· 3. fázis· Epizyme, Inc.· Forrás
Fut, nem toboroz
Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 years old, in good general health and newly diagnosed multiple myeloma.
2024-516905-22-00· 3. fázis· Fundacion PETHEMA· Forrás
Fut, nem toboroz
Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combination with biologic drugs (panitumumab and bevacizumab).
NCT03635021· 3. fázis· Asociacion Grupo Tratamiento De Tumores Digestivos· Forrás
Fut, nem toboroz
Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
NCT03605771· Grupo Español Multidisciplinar de Melanoma· Forrás
Fut, nem toboroz
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
NCT02682641· 2. fázis· Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea· Forrás
Toboroz
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
NCT02832245· Manuel Monreal· Forrás
Contact: María Pérez Morales